• Topline data expected in December 2022 from ongoing Phase IIA multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer's

    Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has submitted a Pre-IND (investigational new drug) meeting request for AL001 and supporting briefing documents to the U.S. Food and Drug Administration ("FDA") for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder ("PTSD").

    AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered…

    View Full Article
    • Topline data expected in December 2022
    • Full data from Phase I first-in-human study demonstrated AL001 in plasma is bioequivalent to the marketed lithium carbonate product

    Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that the first patient with mild to moderate Alzheimer's disease ("Alzheimer's") has been dosed in a 12-month Phase IIA multiple ascending dose ("MAD") study for dementia related to Alzheimer's. The MAD study is for the purpose of evaluating the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determining the maximum…

    View Full Article
    • Full data from Phase 1 first-in-human study demonstrate AL001 in plasma is bioequivalent to the marketed lithium carbonate product
    • Alzamend planning to commence Phase 2A multiple ascending dose study in May 2022

    Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that Digital Power Lending, LLC ("DPL"), a wholly owned subsidiary of BitNile Holdings, Inc. ("NILE") (NYSE:NILE), a diversified holding company, has made an additional investment in the Company.

    On March 28, 2022, Alzamend announced that it has received the full data set from its Phase…

    View Full Article
  1. BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") announced today its wholly owned subsidiary, Digital Power Lending, LLC ("DP Lending") has made an additional investment in Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a related party and early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.

    On March 28, 2022, Alzamend announced the achievement of a key milestone, that it received the full data set from its Phase 1 clinical trial for AL001. The purpose of the Phase 1 first-in-human trial was to determine the pharmacokinetics, safety and tolerability of AL001. These data will help Alzamend…

    View Full Article
  2. The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets

    BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission.

    Year ended December 31, 2021 highlights:

    • Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year;
    • Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending");
    • Revenue from trading activities during the year ended December 31, 2021 included significant net gains on equity securities…
    View Full Article